FDA Will Review Dyne Application for Skipping Exon 51 CureDuchenne was an early funder of Dyne Therapeutics, and we are pleased to share that the FDA has accepted the BLA […]
Italfarmaco reported new data from the Phase 3 EPIDYS trial, showing that quantitative MRI measures of muscle mass and fat fraction were significantly different between the treatment and placebo groups. […]
Proposed text: CureDuchenne was an early funder of Sarepta Therapeutics, and we are pleased to share that the US FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45 […]
As an early funder of Entrada Therapeutics, we are pleased to share their latest newsletter to the Duchenne community. This update includes news that after review of all the data […]
CureDuchenne was an early funder of Dyne Therapeutics, which today announced they have submitted a BLA to the FDA for z-rostudirsen, for the treatment of individuals with Duchenne amenable to […]
Dyne Therapeutics, which received early funding from CureDuchenne, is initiating a Phase 3 FORZETTO Trial of z-rostudirsen in individuals with Duchenne amenable to skipping exon 51. Dyne is on track […]
RegenXBio shared positive topline results from their pivotal Phase 3 AFFINITY DUCHENNE study of RGX-202 in 31 individuals with Duchenne aged 1 year and older. The study met the primary […]
Entrada Therapeutics, who received early funding from CureDuchenne to advance their Endosomal Escape Vehicle Platform, today announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable […]
